Sensorion Appoints Fred Chereau as Chief Executive Officer

About this update from Sensorion Sas

[{"type":"list","items":[{"val":[{"type":"text","content":"Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.","length":229,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.","length":235,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.","length":134,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":598,"olType":false},{"type":"text","content":"MONTPELLIER, France & CAMBRIDGE, Mass., May 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":91,"tagName":"p"},{"type":"text","content":"Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the appointment of Fred Chereau as Chief Executive Officer (CEO), effective June 1, 2026.","length":293,"tagName":"p"},{"type":"text","content":"Fred brings more than 30 years of leadership and operational experience across the biotechnology, pharmaceutical, and medical device industries, combining deep expertise in rare disease drug development and regenerative medicine with a strong track record of building scalable businesses and accelerating growth.","length":312,"tagName":"p"},{"type":"text","content":""I am very pleased to welcome Fred, whose appointment represents a significant step forward for Sensorion and comes at a time of strong momentum across our pipeline. Fred brings an exceptional combination of rare disease expertise, deep familiarity with the gene therapy space, and a track record of high-value business development that will play a key role in accelerating the Company’s programs through their next critical phase. His leadership and business acumen are precisely what Sensorion needs as we approach pivotal milestones, and I look forward to working closely wit...

More updates from Sensorion Sas